New

Polivy 140 mg

₹ 0.00~~₹ 0.00~~

Pronunciation: Poh-LIH-vee
Generic name: Polatuzumab Vedotin
Dosage form: powder for Intravenous Infusion
Drug class: Miscellaneous Antineoplastics

Polivy is a brand-name prescription medication.

Description

Polivy (Polatuzumab Vedotin) 140 mg

Polivy contains Polatuzumab Vedotin, an antibody-drug conjugate used as part of combination treatment for certain types of diffuse large B-cell lymphoma (DLBCL). Polatuzumab Vedotin targets the CD79b protein found on B cells and delivers a cell-killing substance called monomethyl auristatin E (MMAE) into the cancer cells. This helps stop cancer cells from dividing and causes them to die.

Polivy is given as an intravenous infusion under the supervision of a healthcare professional experienced in cancer treatment. It is available as a powder for concentrate for infusion in 30 mg and 140 mg strengths.

Uses of Polivy (Polatuzumab Vedotin)

Previously Untreated Diffuse Large B-Cell Lymphoma

Polivy is used with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP) to treat adults with previously untreated DLBCL. The exact eligibility criteria can depend on the applicable product label and disease risk assessment.

Relapsed or Refractory DLBCL

Polatuzumab Vedotin can also be used with bendamustine and rituximab for adults with DLBCL that has returned or stopped responding after previous treatments. The approved treatment setting varies by regulatory region.

Therapeutic Effects of Polivy

How Polatuzumab Vedotin Works

Polatuzumab Vedotin attaches to CD79b, a protein present on B cells. After binding to the target cell, the medicine enters the cell and releases MMAE. MMAE interferes with microtubules, which are essential for cell division. This action helps destroy malignant B cells.

Treatment Benefits

Polivy is used in combination with other cancer medicines rather than as a standalone treatment. Clinical studies have shown that Polivy-containing treatment regimens can improve disease control in appropriate patients with DLBCL.

Interaction with Other Drugs

Medicines That May Affect Polivy

Tell your doctor about all medicines, supplements, and herbal products you take. Strong CYP3A inhibitors or inducers may affect exposure to the unconjugated MMAE component of Polatuzumab Vedotin. Your doctor will review your medicines before and during treatment.

Vaccines and Infections

Live or live-attenuated vaccines should not be given during Polivy treatment unless specifically advised by your healthcare team. Polatuzumab Vedotin can increase the risk of serious infections, so report fever, persistent cough, chills, or other signs of infection promptly.

More Information About Polivy

Strength and Form

Polivy is supplied as a powder for concentrate for intravenous infusion. Available strengths include 30 mg and 140 mg of Polatuzumab Vedotin per single-dose vial.

Storage

The unopened product should be stored according to the manufacturer’s recommended conditions. The reconstituted and diluted solution should not be frozen or exposed to direct sunlight, and healthcare professionals should prepare Polivy using appropriate aseptic procedures.

How to Administer Polivy

Recommended Dose

The recommended dose of Polatuzumab Vedotin is generally 1.8 mg/kg by intravenous infusion every 21 days for 6 cycles when used in the approved combination regimens. The exact treatment plan depends on the patient’s condition and the accompanying medicines.

Method of Administration

Polivy must be administered through an intravenous infusion. The first infusion is generally given over 90 minutes. If the patient tolerates it well, later infusions may be given over approximately 30 minutes. An antihistamine and antipyretic are given before treatment to reduce the risk of infusion-related reactions.

Important Precautions During Administration

Healthcare professionals monitor the patient during and after the infusion for allergic or infusion-related reactions. Polivy should not be given as an intravenous push or bolus. Proper venous access is important because accidental leakage of the medicine outside the vein can cause tissue injury.

Safety Advice

Breastfeeding

Breastfeeding is not recommended during treatment with Polivy. Speak with your doctor about when breastfeeding can safely resume after treatment.

Alcohol

Avoid or limit alcohol during treatment unless your oncologist says it is safe. Alcohol may worsen treatment-related symptoms and can place additional stress on the liver.

Liver

Tell your doctor if you have liver disease or abnormal liver tests. Polatuzumab Vedotin can cause liver toxicity, including increases in liver enzymes and bilirubin. Doctors may monitor liver function during treatment.

Kidney

Inform your doctor about any kidney problems before receiving Polivy. The recommended dose may depend on kidney function and the available clinical information for your level of renal impairment.

Lungs

Polivy treatment can increase the risk of serious infections, including pneumonia. Report breathing difficulty, persistent cough, fever, or chest discomfort promptly, particularly if these symptoms develop during treatment.

Driving

Polivy and its accompanying treatments may cause fatigue, weakness, dizziness, or other symptoms that can affect alertness. Avoid driving or operating machinery if you do not feel fully alert.

Pregnancy

Polatuzumab Vedotin may harm an unborn baby. Women who can become pregnant should use effective contraception during treatment and for the period recommended by their treating doctor. Current product information specifies different contraception periods depending on the regulatory label.

Side Effects of Polivy

Common Side Effects

Common side effects can include:

Serious Side Effects

Polivy can cause serious side effects such as severe infections, febrile neutropenia, infusion-related reactions, significant peripheral neuropathy, liver toxicity, tumour lysis syndrome, and blood-cell abnormalities. Rare neurological complications such as progressive multifocal leukoencephalopathy (PML) have also been reported.

When to Contact Your Doctor

Contact your healthcare team immediately if you develop severe weakness, numbness or burning in the hands or feet, difficulty walking, high fever, breathing problems, unusual bleeding, severe abdominal symptoms, jaundice, or new neurological or behavioural changes.

Word of Advice

Polivy containing Polatuzumab Vedotin is a specialised cancer medicine that should only be used under the supervision of an experienced oncologist. Do not change the dose, skip treatment, or take additional medicines without medical advice. Regular blood counts, liver tests, and clinical assessments help your healthcare team monitor treatment safety and decide whether treatment needs to continue, pause, or change.